HIV-1 Vpu and BST-2/CD317

HIV-1 Vpu 和 BST-2/CD317

基本信息

项目摘要

DESCRIPTION (provided by applicant): HIV-1 Vpu enhances the release of virions from infected cells by overcoming a cellular inhibitor that retains nascent virions within and on infected cells. The identity of this inhibitor has recently been revealed: it is the transmembrane, GPI-anchored protein BST-2, also known as HM1.24, CD317, or "tetherin." BST-2 seems able to affect diverse enveloped virions, suggesting a broad role in the host defense against viruses including HIV-1. The research proposed here has three specific aims: 1) to reveal how BST-2 retains HIV-1 virions on infected cells; 2) to determine how Vpu antagonizes this restriction; 3) to understand the regulation of BST-2 during the innate immune response and to explore the potential function of BST-2 in antigen presenting cells. These aims will be pursued using a concerted experimental approach including targeted mutagenesis of BST-2 and Vpu, characterization of the interaction between BST-2 and Vpu, analysis of the effects of Vpu on the intracellular trafficking and virion-incorporation of BST-2, and analysis of the regulation and function of BST-2 in primary T lymphocytes and antigen presenting cells. When these aims are completed, we will know how BST-2 retains virions on infected cells, how Vpu counteracts this protein, how BST-2 is regulated during the innate immune response, and whether it plays a role in the uptake of virions by antigen presenting cells during the adaptive immune response. PUBLIC HEALTH RELEVANCE: BST-2 is a newly identified host-cell protein that retains virus particles including those of HIV-1 on infected cells. The HIV-1 protein Vpu counteracts this host defense. This research is designed to explore how BST-2 retains virus particles, how Vpu antagonizes this activity, and how BST-2 is regulated within primary cells of the immune system.
描述(由申请人提供):HIV-1 VPU通过克服一种将新生的病毒粒子保留在感染细胞内和感染细胞上的细胞抑制物来增强受感染细胞中病毒粒子的释放。这种抑制物的身份最近被揭示:它是跨膜的,GPI锚定蛋白BST-2,也被称为HM1.24,CD317,或“tetherin”。BST-2似乎能够影响不同的包膜病毒粒子,这表明在宿主对包括HIV-1在内的病毒的防御中具有广泛的作用。这项研究有三个具体目的:1)揭示BST-2如何将HIV-1病毒粒子保留在感染细胞上;2)确定VPU如何拮抗这一限制;3)了解BST-2在先天免疫反应中的调节,并探索BST-2在抗原提呈细胞中的潜在功能。这些目标将通过一种协调一致的实验方法来实现,包括靶向突变BST-2和VPU,表征BST-2和VPU之间的相互作用,分析VPU对BST-2细胞内运输和病毒粒子掺入的影响,以及分析BST-2在原代T淋巴细胞和抗原提呈细胞中的调节和功能。当这些目标完成后,我们将知道BST-2是如何在感染细胞上保留病毒粒子的,VPU如何抵消这种蛋白质,BST-2在先天性免疫反应中是如何调节的,以及它是否在获得性免疫反应中抗原提呈细胞摄取病毒粒子中发挥作用。与公共卫生相关:BST-2是一种新发现的宿主细胞蛋白,它将包括HIV-1在内的病毒颗粒保留在感染细胞上。HIV-1蛋白VPU抵消了这种宿主防御。这项研究旨在探索BST-2如何保留病毒颗粒,VPU如何拮抗这一活性,以及BST-2如何在免疫系统的原代细胞中受到调节。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John C. Guatelli其他文献

John C. Guatelli的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John C. Guatelli', 18)}}的其他基金

High-Throughput Screening for Multifunctional Nef Inhibitors: Targeting HIV through Revitalizing Immune Defense Mechanisms
多功能 Nef 抑制剂的高通量筛选:通过振兴免疫防御机制靶向 HIV
  • 批准号:
    10116282
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
High-Throughput Screening for Multifunctional Nef Inhibitors: Targeting HIV through Revitalizing Immune Defense Mechanisms
多功能 Nef 抑制剂的高通量筛选:通过振兴免疫防御机制靶向 HIV
  • 批准号:
    10010308
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Activating Latently Infected Cells Using Specific Antigens Including Those of HIV-1
使用特定抗原(包括 HIV-1 抗原)激活潜伏感染细胞
  • 批准号:
    9206464
  • 财政年份:
    2016
  • 资助金额:
    $ 29.93万
  • 项目类别:
Involvement of the C-terminus of HIV-1 Vpu in Enhancement of Virion Release
HIV-1 Vpu C 末端参与增强病毒粒子释放
  • 批准号:
    8790372
  • 财政年份:
    2014
  • 资助金额:
    $ 29.93万
  • 项目类别:
Viral Hijacking of Host Membrane Trafficking Pathways
宿主膜运输途径的病毒劫持
  • 批准号:
    8601167
  • 财政年份:
    2013
  • 资助金额:
    $ 29.93万
  • 项目类别:
Viral Hijacking of Host Membrane Trafficking Pathways
宿主膜运输途径的病毒劫持
  • 批准号:
    8779706
  • 财政年份:
    2013
  • 资助金额:
    $ 29.93万
  • 项目类别:
Inhibiting Immune Evasion by HIV-1 Nef to Facilitate Eradication
抑制 HIV-1 Nef 的免疫逃避以促进根除
  • 批准号:
    8656289
  • 财政年份:
    2013
  • 资助金额:
    $ 29.93万
  • 项目类别:
Inhibiting Immune Evasion by HIV-1 Nef to Facilitate Eradication
抑制 HIV-1 Nef 的免疫逃避以促进根除
  • 批准号:
    8770025
  • 财政年份:
    2013
  • 资助金额:
    $ 29.93万
  • 项目类别:
Viral Hijacking of Host Membrane Trafficking Pathways
宿主膜运输途径的病毒劫持
  • 批准号:
    8542438
  • 财政年份:
    2013
  • 资助金额:
    $ 29.93万
  • 项目类别:
ULTRASTRUCTURAL LOCALIZATION OF THE HOST ANTIVIRAL PROTEIN BST-2
宿主抗病毒蛋白 BST-2 的超微结构定位
  • 批准号:
    8361924
  • 财政年份:
    2011
  • 资助金额:
    $ 29.93万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 29.93万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了